Krish Patel

Join Krish Patel, an expert in mantle cell lymphoma from the Sarah Cannon Cancer Institute, and David Lewis from Plymouth University, as they discuss the groundbreaking role of BTK inhibitors in treating relapsed/refractory MCL. They explore innovative combination strategies to tackle resistance and enhance treatment efficacy. The conversation highlights the importance of personalized therapy and the evolving landscape of BTK inhibitor selection, particularly in the UK. Their insights reveal promising future directions in MCL management.

Join experts Krish Patel, MD, specializing in mantle cell lymphoma treatment, Marek Trněný, MD, PhD, a key contributor to BTK inhibitor trials, and Michael Wang, MD, who offers insights on therapeutic sequencing. They delve into groundbreaking trials like ECHO and SHINE, discussing the role of BTK inhibitors and their effectiveness for older patients. Notably, they address optimal sequencing methods to prevent cross-resistance and strategies for managing cardiac toxicities. Their collaboration underscores a comprehensive approach to enhancing patient care.

Dr. Krish Patel from the Swedish Cancer Institute discusses novel therapies for DLBCL, focusing on bispecific antibody gilteritinib. They compare bispecifics to CAR T-cell therapy, explore fixed duration therapy, step-up dosing, and sequencing therapy for optimal results.